Sygnature Discovery, a leading drug discovery contract research organisation (CRO), has today announced a strategic brand relaunch, including a new website, cementing its position as a global drug discovery partner.

For more than 20 years, Sygnature has built a strong reputation for delivering high quality candidates. Continued investment and strategic acquisitions have enabled the company to support customers across the full drug discovery process, from target identification to candidate nomination.

Uniquely positioned as the only CRO offering full Design, Make, Test, Analyze (DMTA) capabilities under one roof in both North America and Europe, Sygnature is now targeting increased awareness and market share on a global scale.

Over recent years, Sygnature has integrated several complementary businesses, strengthening its scientific breadth, scale and geographic footprint. Today, its capabilities span bioscience, protein science & structural biology, synthetic & medicinal chemistry, computer‑aided drug design, drug metabolism & pharmacokinetics (DMPK), in vivo pharmacology, and form & formulation, all delivered through co‑located, multidisciplinary teams.

“We’ve grown significantly in scale and capability over the past two decades,” said Dr. Simon Hirst, CEO of Sygnature Discovery. “Biotech and pharma companies are facing volatile investment conditions, tighter timelines and rising costs. Our truly integrated approach is built around helping customers navigate that reality — whether they’re outsourcing a whole programme or need expert input in a single discipline.

“By bringing together multidisciplinary expertise in co‑located teams, supported by AI and automation, we help customers move faster and improve the quality of their decisions. Across Europe and North America, we act as an extension of our customers’ teams, delivering a service they can trust.”